Table 1.
Baseline demographic, clinical, and pathological characteristics of the patient cohort.
| Characteristic | Patients (n = 63) |
|---|---|
| Median age in years (IQR) | 76.8 (71–79.5) |
| Prostatectomy, no (%) | 35 (55.6) |
| Adjuvant radiotherapy, no (%) | 21 (33.3) |
| Time since diagnosis of bone metastases (years), median (IQR) | 2 (1–4) |
| Concomitant disease | |
| Cardiologic, no (%) | 36 (57.1) |
| Endocrinology, no (%) | 20 (31.7) |
| Cerebral, no (%) | 5 (7.9) |
| Respiratory, no (%) | 2 (3.2) |
| Neurologic/psychiatric, no (%) | 3 (4.8) |
| Musculoskeletal, no (%) | 4 (6.4) |
| Renal, no (%) | 10 (15.9) |
| Other cancers, no (%) | 7 (11.1) |
| Other, no (%) | 6 (9.5) |
| Chemotherapy-naive, no (%) | 11 (17.4) |
| 1 Line of therapy before 223-Ra, n (%) | 52 (82.5) |
| 2 Lines of therapy before 223-Ra, n (%) | 33 (52.4) |
| 3 Lines of therapy before 223-Ra, n (%) | 17 (27) |
| 4 Lines of therapy before 223-Ra, n (%) | 6 (9.5) |
| 5 Lines of therapy before 223-Ra, n (%) | 1(1.6%) |
| Radium-223 treatment | |
| First-line | 11 (17.5) |
| Second-line | 19 (30.5) |
| Third-line | 16 (25.4) |
| Fourth-line | 11(17.5) |
| Fifth-line | 6 (9.5) |
| ECOG performance status, no. (%) | |
| 0 | 46 (74.2) |
| 0/1 | 5 (8.1) |
| 1 | 5 (8.1) |
| 2 | 6 (9.7) |
| Bone scan lesions, no. (%) | |
| <6 | 5 (7.9) |
| 6–20 | 33 (52.4) |
| >20 | 16 (25.4) |
| Unknown | 9 (14.3) |
| Median biochemistry (IQR) | |
| PSA prior to first 223Ra cycle, ng/mL | 48.4 (17.8–131) |
| ALP prior to first 223Ra cycle, µg/L | 138 (79–288) |
| Initial NRS pain score prior to first 223Ra cycle, median (IQR) | 3 (2–5.5) |
| Hb levels prior to first 223-Ra cycle, g/dL, mean (DS) | 12.2 (1.3) |